Core Viewpoint - The Schall Law Firm is investigating potential fraud claims against Disc Medicine, Inc. (NASDAQ: IRON) related to violations of securities laws, particularly concerning misleading statements and undisclosed information impacting investors [1]. Group 1: Company Overview - Disc Medicine, Inc. is currently facing scrutiny due to a delay in the review timeline of its experimental drug, which was flagged by U.S. FDA scientists for safety and efficacy concerns [1]. - Following the news of the FDA's concerns, shares of Disc Medicine fell by more than 7.8% on the same day [1]. Group 2: Legal Investigation - The Schall Law Firm is encouraging shareholders who have suffered losses to participate in the investigation and to contact them for a free discussion of their rights [1]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [1].

Lilly halts a study of an experimental drug designed to prevent obesity patients from losing too much muscle, citing strategic business reasons https://t.co/isjH65RANR ...

BioNTech said an experimental drug succeeded in a breast cancer study, the first dividend of the German Covid-19 vaccine maker’s collaboration with Chinese biotech Duality https://t.co/gka8vlNf2z ...

Clinical Trial Results - Mineralys Therapeutics 的一种实验性药物显著降低了治疗抵抗性高血压患者的血压 [1] - 一些患者因副作用停止服用该药物 [1]